August 2021 - QuartzBio

August 31, 2021 — Clinical samples are moving across an increasing number of physical/virtual locations and data is delivered in an expanding array of file formats as clinical trials become increasingly more complex and data rich (report).

Biospecimens are analyzed using a variety of assay technologies, each generating its own set of reportables, quality control metrics and data/file formats. Data is delivered through multiple, disconnected pipelines (Figure 1).

This complexity creates obstacles for many functional groups within sponsor organizations:

Title: Transcending Biomarker Data Chaos: How Integrating Disparate PK, Clinical & Exploratory Data Enables Deep Translational Insights

Duration: 30 minutes

You will see how teams unlock translational intelligence:

Navigate vast exploratory data – identify trends and data points of interest
Surface insights – analyze biomarker trends in collaborative dashboards across subject IDs, time points, response status, and treatment groups
Access data rapidly – point and click navigation to underlying data files to interrogate the raw data behind the summary values
Interrogate cross assay – map to a common data dictionary to enable rapid interrogation of trends across assay modalities: within and across studies

Precision for Medicine is the first biomarker-driven clinical development organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments. Precision for Medicine is part of Precision Medicine Group, with 3,000 employees in 40 locations.

Web Design and Development by RainCastle Communications.